Dr Paul Ridker discusses his paper on residual inflammatory risk that was recently published in the Lancet with Dr. Thomas Nero. He discusses the pathology of inflammation as part of atherosclerosis, utilization of hs-CRP in clinical trials and in daily practice as well as current therapeutic options and ongoing investigations.